Most Read Articles
Pearl Toh, 4 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

Dr Renly Lim, 01 Aug 2018
Palliative care uses an integrated, multidisciplinary approach to reduce suffering and to improve the quality of life of patients battling with life-threatening illnesses.
Audrey Abella, 28 Nov 2018
Use of the oral anticoagulant rivaroxaban at a low dose may reduce the risk of thromboembolic events* in patients with heart failure (HF), according to a post hoc analysis of the COMMANDER HF** trial.

Halobetasol propionate with tazarotene effective, safe for psoriasis

22 Jul 2018
Psoriasis affecting the upper limb

Halobetasol propionate plus tazarotene (HP/TAZ) significantly reduces the clinical severity of psoriasis with minimal adverse side effects, a recent study has shown.

The present analysis included data from two randomized, double-blind, multicentre, controlled phase 3 studies, where 418 psoriasis patients (65.1 percent male) were randomly assigned 2:1 to receive HP/TAZ lotion or vehicle control once daily for 8 weeks. The study outcomes included treatment success and safety.

At week 8, 35.8 percent (study 1) and 45.3 percent (study 2) of the participants who received HP/TAZ achieved the primary efficacy outcome of at least a 2-grade improvement in Investigator’s Global Assessment score from baseline. This was significantly higher than in the vehicle control groups (7.0 and 12.5 percent, respectively; p<0.001 for both).

Similarly, at the same time point in study 1 and study 2, significantly more participants in the HP/TAZ vs vehicle control group showed improvements in erythema (44.2 percent and 49.6 percent vs 10.0 percent and 18.7 percent) and plaque elevation (59.3 percent and 59.7 percent vs 17.9 percent and 21.3 percent; p<0.001 for all).

In terms of safety, adverse events were more common in participants who received the HP/TAZ lotion than in those who received the control (35.9 percent vs 21.4 percent). Majority of the adverse events (AEs) were mild or moderate in severity (85.6 percent); only three serious AEs were reported, none of which were related to the HP/TAZ lotion,

The most common treatment-related AEs were contact dermatitis, pruritus and pain the application site.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 4 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

Dr Renly Lim, 01 Aug 2018
Palliative care uses an integrated, multidisciplinary approach to reduce suffering and to improve the quality of life of patients battling with life-threatening illnesses.
Audrey Abella, 28 Nov 2018
Use of the oral anticoagulant rivaroxaban at a low dose may reduce the risk of thromboembolic events* in patients with heart failure (HF), according to a post hoc analysis of the COMMANDER HF** trial.